I hold a PhD and MSc in health economics and have been a professor of health economics since 2009. Since 2011, I’ve also served as a member of the arbitration board for drug prices in Germany’s statutory health insurance system (Schiedsstelle nach § 130b SGB V). From March 2000 to June 2005, I was the managing director of a health economics consultancy, which was later acquired by IMS HEOR. Following the acquisition, I worked as a full-time principal at IMS HEOR in Germany until August 2009.

Prior to founding the consultancy, I spent several years in the pharmaceutical industry, focusing on health economics, pricing, and health policy. My current focus lies in market access strategies, pricing, health policy, and health economic evaluations—including cost analysis, economic modeling, and cost-effectiveness analysis. I bring experience across a wide range of therapeutic areas and disease states.